Hillevax Inc (HLVX) - Net Assets
Based on the latest financial reports, Hillevax Inc (HLVX) has net assets worth $147.82 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($174.91 Million) and total liabilities ($27.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hillevax Inc (HLVX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $147.82 Million |
| % of Total Assets | 84.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.59 |
Hillevax Inc - Net Assets Trend (2019–2024)
This chart illustrates how Hillevax Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Hillevax Inc for the complete picture of this company's asset base.
Annual Net Assets for Hillevax Inc (2019–2024)
The table below shows the annual net assets of Hillevax Inc from 2019 to 2024. For live valuation and market cap data, see HLVX company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $154.49 Million | -41.82% |
| 2023-12-31 | $265.52 Million | -0.64% |
| 2022-12-31 | $267.23 Million | +365.22% |
| 2021-12-31 | $-100.76 Million | -3533.50% |
| 2020-12-31 | $-2.77 Million | -313.26% |
| 2019-12-31 | $-671.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hillevax Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53515300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $-1.14 Million | -0.74% |
| Other Components | $691.45 Million | 447.58% |
| Total Equity | $154.49 Million | 100.00% |
Hillevax Inc Competitors by Market Cap
The table below lists competitors of Hillevax Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ABCO Electronics Co. Ltd
KQ:036010
|
$104.77 Million |
|
BH Macro Limited
LSE:BHMU
|
$104.78 Million |
|
KG Mobilians Co. Ltd
KQ:046440
|
$104.80 Million |
|
Ever Ohms Technology Co. Ltd.
TW:6834
|
$104.80 Million |
|
BAPCOR LTD.
F:0BS
|
$104.76 Million |
|
Champion Building Materials Co Ltd
TW:1806
|
$104.73 Million |
|
Bank Pembangunan Timur Tbk
JK:BJTM
|
$104.72 Million |
|
Singha Estate Public Company Limited
BK:S
|
$104.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hillevax Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 265,525,000 to 154,486,000, a change of -111,039,000 (-41.8%).
- Net loss of 147,267,000 reduced equity.
- New share issuances of 15,677,000 increased equity.
- Other comprehensive income decreased equity by 233,000.
- Other factors increased equity by 20,784,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-147.27 Million | -95.33% |
| Share Issuances | $15.68 Million | +10.15% |
| Other Comprehensive Income | $-233.00K | -0.15% |
| Other Changes | $20.78 Million | +13.45% |
| Total Change | $- | -41.82% |
Book Value vs Market Value Analysis
This analysis compares Hillevax Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.02 | $2.09 | x |
| 2020-12-31 | $-0.09 | $2.09 | x |
| 2021-12-31 | $-3.34 | $2.09 | x |
| 2022-12-31 | $7.10 | $2.09 | x |
| 2023-12-31 | $6.54 | $2.09 | x |
| 2024-12-31 | $3.14 | $2.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hillevax Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -95.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-95.33%) is below the historical average (-39.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-605.90K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.85 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-74.95 Million |
| 2022 | -96.17% | 0.00% | 0.00x | 1.19x | $-283.73 Million |
| 2023 | -46.54% | 0.00% | 0.00x | 1.30x | $-150.12 Million |
| 2024 | -95.33% | 0.00% | 0.00x | 1.25x | $-162.72 Million |
Industry Comparison
This section compares Hillevax Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hillevax Inc (HLVX) | $147.82 Million | 0.00% | 0.18x | $104.76 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more